Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N; French COVID cohort management committee, CoV-CONTACT study group; members of the French-COVID cohort study group (by alphabetical order); member of the CoV-CONTACT study group. Principal investigator; Steering Committee; CoV-CONTACT Clinical Centers; Coordination and statistical analyses; Virological Lab; Biological Center; Partners; Sponsor; Genetic. Hingrat QL, et al. Among authors: yazdanpanah y. Clin Microbiol Infect. 2020 Dec 8;27(5):789.e1-5. doi: 10.1016/j.cmi.2020.11.025. Online ahead of print. Clin Microbiol Infect. 2020. PMID: 33307227 Free PMC article.
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS 139 TRIO Trial study group. Charpentier C, et al. Among authors: yazdanpanah y. AIDS. 2010 Nov 13;24(17):2651-6. doi: 10.1097/QAD.0b013e32833ed2a7. AIDS. 2010. PMID: 20802293 Clinical Trial.
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D. Charpentier C, et al. Among authors: yazdanpanah y. J Antimicrob Chemother. 2012 Jun;67(6):1459-61. doi: 10.1093/jac/dks067. Epub 2012 Mar 1. J Antimicrob Chemother. 2012. PMID: 22382470
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group. Charpentier C, et al. Among authors: yazdanpanah y. PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621. Epub 2013 Jan 17. PLoS One. 2013. PMID: 23349724 Free PMC article. Clinical Trial.
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
Fofana DB, Charpentier C, Maïga AI, Lambert-Niclot S, Sayon S, Désiré N, Simon A, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG, Soulié C. Fofana DB, et al. Among authors: yazdanpanah y. J Antimicrob Chemother. 2015 Jan;70(1):130-5. doi: 10.1093/jac/dku360. Epub 2014 Sep 30. J Antimicrob Chemother. 2015. PMID: 25270328
723 results